申请人:Denali Therapeutics Inc.
公开号:US11236100B2
公开(公告)日:2022-02-01
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
本公开一般涉及真核启动因子 2B 调节剂或其药学上可接受的盐、立体异构体、立体异构体混合物或原药,以及其制造和使用方法。